NASDAQ:SYBX Synlogic (SYBX) Stock Forecast, Price & News $0.33 -0.01 (-2.91%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$0.31▼$0.3650-Day Range$0.25▼$0.5452-Week Range$0.24▼$1.35Volume79,905 shsAverage Volume184,258 shsMarket Capitalization$22.91 millionP/E RatioN/ADividend YieldN/APrice Target$6.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Synlogic MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,796.2% Upside$6.33 Price TargetShort InterestHealthy0.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.60Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.92) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.50 out of 5 starsMedical Sector185th out of 966 stocksPharmaceutical Preparations Industry68th out of 450 stocks 3.5 Analyst's Opinion Consensus RatingSynlogic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.33, Synlogic has a forecasted upside of 1,796.2% from its current price of $0.33.Amount of Analyst CoverageSynlogic has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.44% of the float of Synlogic has been sold short.Short Interest Ratio / Days to CoverSynlogic has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Synlogic has recently decreased by 25.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSynlogic does not currently pay a dividend.Dividend GrowthSynlogic does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SYBX. Previous Next 3.7 News and Social Media Coverage News SentimentSynlogic has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Synlogic this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SYBX on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat Follows1 people have added Synlogic to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Synlogic insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.01% of the stock of Synlogic is held by insiders.Percentage Held by Institutions47.18% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Synlogic are expected to grow in the coming year, from ($0.92) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Synlogic is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Synlogic is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSynlogic has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Synlogic (NASDAQ:SYBX) StockSynlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.Read More SYBX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYBX Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comSynlogic to Participate in Chardan’s Genetic Medicines ConferenceSeptember 19, 2023 | finance.yahoo.comSynlogic Announces CEO Aoife Brennan Named to PharmaVoice 100September 23, 2023 | MarketBeat Internal (Ad)MarketBeat's Top 5 Stock Picks - Just ReleasedMarketBeat has just released five new trading ideas to All Access subscribers, but Tesla, Apple, and Netflix didn't make the cut. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Now, MarketBeat thinks these five stocks may be even better buys. September 14, 2023 | americanbankingnews.comSynlogic (NASDAQ:SYBX) Stock Passes Below 50 Day Moving Average of $0.49August 12, 2023 | msn.comChardan Capital Reiterates Synlogic (SYBX) Buy RecommendationAugust 11, 2023 | markets.businessinsider.comSynlogic (SYBX) Receives a Buy from H.C. WainwrightAugust 11, 2023 | markets.businessinsider.comExpert Ratings for SynlogicAugust 10, 2023 | finance.yahoo.comSynlogic, Inc. (SYBX) Reports Q2 Loss, Misses Revenue EstimatesSeptember 23, 2023 | MarketBeat Internal (Ad)MarketBeat's Top 5 Stock Picks - Just ReleasedMarketBeat has just released five new trading ideas to All Access subscribers, but Tesla, Apple, and Netflix didn't make the cut. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Now, MarketBeat thinks these five stocks may be even better buys. August 10, 2023 | finance.yahoo.comSynlogic Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 11, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for SynlogicJuly 11, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Synlogic (SYBX)July 11, 2023 | finance.yahoo.comSynlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of PhenylketonuriaJuly 6, 2023 | msn.comSynlogic (SYBX) Price Target Decreased by 11.11% to 5.10June 28, 2023 | finance.yahoo.comSynlogic Announces International Nonproprietary Name Selection for SYNB1934June 28, 2023 | finance.yahoo.comSynlogic Announces International Nonproprietary Name Selection for SYNB1934June 27, 2023 | finance.yahoo.comSynlogic Announces Participation in SVB Securities Healthcare Therapeutics ForumJune 8, 2023 | finance.yahoo.comSynlogic Reminds Stockholders of 2023 Annual General Meeting DetailsJune 7, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Synlogic (SYBX)June 6, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About SynlogicJune 6, 2023 | msn.comChardan Capital Maintains Synlogic (SYBX) Buy RecommendationJune 5, 2023 | finance.yahoo.comSynlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of PhenylketonuriaMay 24, 2023 | finance.yahoo.comSynlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) ConferenceMay 23, 2023 | finance.yahoo.comSynlogic to Present at the Jefferies Global Healthcare ConferenceMay 16, 2023 | msn.comHC Wainwright & Co. Reiterates Synlogic (SYBX) Buy RecommendationMay 15, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Synlogic (SYBX)May 13, 2023 | finance.yahoo.comSynlogic First Quarter 2023 Earnings: Beats ExpectationsSee More Headlines Receive SYBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter. Email Address SYBX Company Calendar Last Earnings8/10/2023Today9/23/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYBX CUSIPN/A CIK1527599 Webwww.synlogictx.com Phone(617) 401-9975Fax512-681-5201Employees72Year Founded2013Price Target and Rating Average Stock Price Forecast$6.33 High Stock Price Forecast$8.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+1,796.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,150,000.00 Net Margins-6,573.82% Pretax Margin-6,572.91% Return on Equity-85.18% Return on Assets-63.40% Debt Debt-to-Equity RatioN/A Current Ratio5.14 Quick Ratio5.15 Sales & Book Value Annual Sales$1.18 million Price / Sales19.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book0.29Miscellaneous Outstanding Shares68,600,000Free Float63,109,000Market Cap$22.91 million OptionableNot Optionable Beta0.96 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Aoife M. Brennan BAO (Age 47)BCh, M.D., MB, MMSc, Pres, CEO & Director Comp: $872.09kMr. Michael JensenChief Financial OfficerMr. Antoine Awad (Age 43)Chief Operating Officer Comp: $566.55kDr. Timothy K. Lu M.D. (Age 42)Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. James J. Collins Ph.D. (Age 57)Co-Founder & Member of Scientific Advisory Board Mr. Brendan St. AmantGen. Counsel & Corp. Sec.Mr. Ajay MunshiVP of Corp. Devel.Mr. Adam ThomasChief People OfficerDr. Caroline B. Kurtz Ph.D.Chief Devel. OfficerMs. Molly Harper (Age 46)Chief Bus. Officer More ExecutivesKey CompetitorsHepion PharmaceuticalsNASDAQ:HEPASensei BiotherapeuticsNASDAQ:SNSEAcurx PharmaceuticalsNASDAQ:ACXPYS BiopharmaNASDAQ:YSAlzamend NeuroNASDAQ:ALZNView All CompetitorsInsiders & InstitutionsBlackRock Inc.Sold 151,765 shares on 8/11/2023Ownership: 0.440%Renaissance Technologies LLCBought 122,400 shares on 8/11/2023Ownership: 0.314%PVG Asset Management CorpSold 31,765 shares on 7/31/2023Ownership: 0.100%Harbor Capital Advisors Inc.Bought 26,579 shares on 7/11/2023Ownership: 0.426%Aoife BrennanSold 19,042 sharesTotal: $11,044.36 ($0.58/share)View All Insider TransactionsView All Institutional Transactions SYBX Stock - Frequently Asked Questions Should I buy or sell Synlogic stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYBX shares. View SYBX analyst ratings or view top-rated stocks. What is Synlogic's stock price forecast for 2023? 3 Wall Street research analysts have issued 12-month price objectives for Synlogic's stock. Their SYBX share price forecasts range from $5.00 to $8.00. On average, they predict the company's share price to reach $6.33 in the next twelve months. This suggests a possible upside of 1,796.2% from the stock's current price. View analysts price targets for SYBX or view top-rated stocks among Wall Street analysts. How have SYBX shares performed in 2023? Synlogic's stock was trading at $0.76 at the beginning of 2023. Since then, SYBX stock has decreased by 56.1% and is now trading at $0.3340. View the best growth stocks for 2023 here. Are investors shorting Synlogic? Synlogic saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 192,400 shares, a decrease of 25.7% from the August 15th total of 259,100 shares. Based on an average trading volume of 188,100 shares, the short-interest ratio is presently 1.0 days. Approximately 0.4% of the shares of the stock are sold short. View Synlogic's Short Interest. When is Synlogic's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our SYBX earnings forecast. How were Synlogic's earnings last quarter? Synlogic, Inc. (NASDAQ:SYBX) announced its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. The biotechnology company earned $0.04 million during the quarter, compared to the consensus estimate of $0.18 million. Synlogic had a negative trailing twelve-month return on equity of 85.18% and a negative net margin of 6,573.82%. When did Synlogic's stock split? Synlogic shares reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of Synlogic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM). What is Synlogic's stock symbol? Synlogic trades on the NASDAQ under the ticker symbol "SYBX." Who are Synlogic's major shareholders? Synlogic's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.44%), Harbor Capital Advisors Inc. (0.43%), Renaissance Technologies LLC (0.31%) and PVG Asset Management Corp (0.10%). Insiders that own company stock include Antoine Awad, Aoife Brennan and Michael Vangsted Jensen. View institutional ownership trends. How do I buy shares of Synlogic? Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Synlogic's stock price today? One share of SYBX stock can currently be purchased for approximately $0.33. How much money does Synlogic make? Synlogic (NASDAQ:SYBX) has a market capitalization of $22.91 million and generates $1.18 million in revenue each year. The biotechnology company earns $-66,150,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. How can I contact Synlogic? Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The official website for the company is www.synlogictx.com. The biotechnology company can be reached via phone at (617) 401-9975, via email at liz@synlogictx.com, or via fax at 512-681-5201. This page (NASDAQ:SYBX) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.